Sun Pharma settles Ethyol dispute with MedImmune

Sun Pharmaceutical Industries Ltd today said on that it has, along with its subsidiaries, settled a patent dispute with AstraZeneca unit MedImmune for generic version of Ethyol, resolving all litigation between them.

In a statement to the Bombay Stock exchange, it said it has executed a settlement agreement with MedImmune, stipulating the dismissal of the lawsuits filed in the United States District Court for the District o f Maryland regarding the submission of abbreviated new drug application (ANDA) for a generic version of Ethyol.

Under the settlement agreement, MedImmune inter alia grants Sun Pharma a license to certain patents, permitting Sun Pharma to continue marketing the generic version of Ethyol in the United States. The settlement resolves all litigation between the parties.

Ethyol is used to reduce toxicities associated Ethyol is used to reduce toxicities associated with certain types of cancer chemotherapy and radiotherapy.